Cargando…

Factors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study

BACKGROUND: Diabetic macular oedema (DMO) is the leading cause of sight impairment in working age populations in developed countries. Current first line treatment for centre-involving DMO involves intravitreal anti-VEGF but treatment response can be variable. In this retrospective, real world, multi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sim, Sing Yue, Ghulakhszian, Arevik, Minocha, Amal, Ramcharan, Dhannie, Nokhostin, Soroush, Cheong-Leen, Richard, George, Sheena, Posner, Esther, Dinah, Christiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144175/ https://www.ncbi.nlm.nih.gov/pubmed/34045845 http://dx.doi.org/10.2147/OPTH.S314614

Ejemplares similares

Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
por: Dinah, Christiana, et al.
Publicado: (2021)

Correction: Aflibercept for treatment-naïve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
por: Dinah, Christiana, et al.
Publicado: (2021)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study
por: Enoch, Jamie, et al.
Publicado: (2021)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)

Towards a Therapy for Geographic Atrophy: A Patient’s Experience
por: Enoch, Jamie, et al.
Publicado: (2023)

Piloting a forced-choice task to elicit treatment preferences in geographic atrophy
por: Enoch, Jamie, et al.
Publicado: (2023)

Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study
por: Enoch, Jamie, et al.
Publicado: (2023)

A Review of Aflibercept Treatment for Macular Disease
por: Anguita, Rodrigo, et al.
Publicado: (2021)

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
por: McCloskey, Clare F., et al.
Publicado: (2018)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

Correction to: A Review of Aflibercept Treatment for Macular Disease
por: Anguita, Rodrigo, et al.
Publicado: (2021)

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020)

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema
por: Pearce, Ian, et al.
Publicado: (2019)

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
por: Kern, Christoph, et al.
Publicado: (2020)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48‐month follow‐up study
por: Angermann, Reinhard, et al.
Publicado: (2021)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study
por: O’Day, Roderick, et al.
Publicado: (2020)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2021)

Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years
por: Talks, S. J., et al.
Publicado: (2021)

Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study
por: Arai, Yusuke, et al.
Publicado: (2023)

Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
por: Amoaku, Winfried M., et al.
Publicado: (2020)

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
por: Strong, Stacey A., et al.
Publicado: (2016)

Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings
por: Sepetis, Anastasios E., et al.
Publicado: (2022)

Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
por: Sydnor, Shelby, et al.
Publicado: (2023)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

The role of aflibercept in the management of diabetic macular edema
por: Chang, Andrew A, et al.
Publicado: (2015)

The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015)

Optical coherence tomography imaging of macular oedema
por: Trichonas, George, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gga3fcigms94olag1uun274riq